Series RIKV 26 0318Settlement Date 09/17/2025Total Amount Allocated (MM) 21,018All Bids Awarded At (Price / Simple interest) 96.300/7.600Total Number of Bids Received 25Total Amount of All Bids Received (MM) 31,718Total Number of Successful Bids 18Number of Bids Allocated in Full 18Lowest Price / Highest Simple Interest Allocated 96.300/7.600Highest Price / Lowest Simple Interest Allocated 96.352/<td style="border-right: solid black 1pt ; text-align: right ; vertical-align: m ...

The crypto market is down today, with the cryptocurrency market capitalization dropping 0.4% to $4.15 trillion. Most of the top 100 coins have decreased over the past 24 hours. At the same time, the total crypto trading volume is at $130 billion. TLDR: The crypto market capitalization is down 0.4% on Monday morning (UTC); 14 of the top 100 coins are green, only BTC is up in the top 10 category; BTC is up to $116,309, and ETH is down to $4,642; ’The bull run is not over, there’s still substantial upside ah ...

AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in its home market. ...

XPeng Inc. (NYSE:XPEV) has partnered with Magna International Inc. (NYSE:MGA) to assemble two electric vehicle models in Europe. Production is slated to start in the third quarter of 2025. The agreement makes XPeng the first Chinese automaker to localize production at Magna’s facilities on the continent. The EVs will be manufactured at Magna’s plant in Graz, Austria. The move highlights the growing importance of localized production as Chinese automakers expand in Europe. Also Read: XPeng Owners Warned As ...

Group 1 - Australian mining company MMG, backed by China Minmetals Corporation, is seeking EU approval for its $500 million acquisition of Anglo American's nickel assets [1][2] - The acquisition is part of Anglo American's restructuring strategy following a successful defense against a takeover bid from BHP [2] - MMG's corporate relations executive general manager expressed confidence in obtaining regulatory clearance due to the company's absence from the ferronickel market and lack of operations in Brazil [3][4] Group 2 - The deal has faced criticism from organizations like the American Iron and Steel Institute, which argues it could enhance China's control over nickel, a critical component in electric vehicle production and stainless steel manufacturing [5] - MMG anticipates a decision from the EU regarding the acquisition before the end of the year [5] - The company initially sought expedited approval but withdrew the application in May [6]

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Celanese (CE) is a global hybrid chemical company which makes high performance engineered polymers that are used in a range of high-value applications. The Zacks Consensus Estimate for its current year earnings has been revised almost 14.2% downward over the last 60 days.Elevance Health, Inc. (ELV) is one of the largest publicly traded health insurers in the United States. The Zacks Consensus Estimate for its current year earnings has ...

Group 1 - Jim Wyckoff has over 25 years of experience in stock, financial, and commodity markets [1] - He has worked as a financial journalist and covered various futures markets in the U.S. [1] - Jim is the proprietor of an analytical, educational, and trading advisory service [2] Group 2 - He has held positions as a technical analyst for Dow Jones Newswires and as a senior market analyst with TraderPlanet.com [2] - Jim has also been a consultant for the "Pro Farmer" agricultural advisory service [2] - He was the head equities analyst at CapitalistEdge.com [2] Group 3 - Jim provides daily market roundups and technical analysis on Kitco.com [3]

COVINGTON, La.--(BUSINESS WIRE)--Globalstar, Inc. (NASDAQ: GSAT), a next-generation telecommunications infrastructure and technology provider, today announces plans to bring-into-use its HIBLEO-XL-1 satellite system filing in preparation for its next era of mobile satellite connectivity. Dr. Paul Jacobs, Globalstar CEO, said "We believe that bringing HIBLEO-XL-1 into use provides Globalstar with significant optionality as the Company grows as a major provider of connectivity in the global space. ...

Core Insights - Alterity Therapeutics announced positive results from the ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA), demonstrating clinically meaningful efficacy in modifying disease progression at both 50 mg and 75 mg doses [1][2][3] Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly MSA and Parkinson's disease [4][8] - The lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, showing preclinical efficacy in reducing α-synuclein pathology and restoring normal iron balance in the brain [4][8] Clinical Trial Details - The ATH434-201 Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study involving 77 adults, assessing the efficacy, safety, and pharmacokinetics of ATH434 over 12 months [5][6] - Results indicated that ATH434 produced clinically and statistically significant improvements on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, with additional positive trends in motor performance and patient-reported outcomes [5][6] Efficacy and Safety - ATH434 demonstrated target engagement by reducing iron accumulation in MSA-affected brain regions, with both dose levels showing a favorable safety profile comparable to placebo [2][5] - The study reported no serious adverse events attributed to ATH434, reinforcing its tolerability [2][6] Regulatory Status - ATH434 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and the European Commission for the treatment of MSA, highlighting its potential as a significant therapeutic option in a market with currently no approved disease-modifying treatments [4][8]

Core Insights - The Renewable Energy Zone (REZ) project in New South Wales (NSW) has received planning approval to enhance grid infrastructure and support renewable energy generation [1][4] - The project aims to provide 1GW of transfer capacity through improvements to distribution lines and the establishment of two new substations [1] - The REZ is expected to create approximately 590 direct jobs during construction, focusing on local employment [2] Infrastructure Development - The REZ will involve upgrading existing distribution poles and wires to minimize community and environmental impact [5] - The project is part of a broader strategy to phase out coal-fired power stations and ensure a reliable electricity supply [2][3] - Ausgrid has been selected as the preferred network operator and will address community feedback regarding various project aspects [5][6] Renewable Energy Goals - Currently, around 36% of electricity in NSW is generated from renewable sources, with the REZ expected to contribute significantly to achieving over two-thirds of the state's 2030 renewable energy generation goal [3] - The project aligns with NSW's long-duration storage target, aiming for approximately 40% by 2030 [3] - The REZ initiative is crucial for the state's energy strategy as it transitions away from coal dependency [3][4]